The Fujifilm Group offers drug discovery support solutions, including cell culture media, reagents, and iPS cells, alongside its CDMO services. It provides comprehensive support to a wide range of customers, including pharmaceutical companies, biotech ventures, and academia, from early-stage drug development through commercial production. Under the guiding principle of being “Partners for Life,” the company strives to be a trusted partner in advancing healthcare and delivering innovative therapies to patients worldwide.
[1] Contract Development & Manufacturing Organization. Provides a wide range of services to pharmaceutical companies, including process development, stability testing, clinical drug development and manufacturing, and commercial production.
[2] Single-use components used in biopharmaceutical manufacturing processes. Compared to traditional stainless-steel systems, single-use equipment eliminates the need for cleaning and sterilization, enhancing flexibility and efficiency, and has become widely adopted in recent years.
[3] Combines an antibody with a drug such as an anticancer agent. By binding the antibody to antigens present on the surface of cancer cells, ADCs enable targeted delivery of the drug, offering high therapeutic efficacy with fewer side effects.
[4] According to trade statistics from Japan’s Ministry of Finance (Export Statistical Item Classification No. 30.02), Japan recorded a biopharmaceutical trade deficit of JPY1.7 trillion in 2024.